the following records until 5 years after the date they are created, and shall make them available for inspection or copying in accordance with section 11 of TSCA:

1. Records of the quantity of the TME substance produced and the date of manufacture.
2. Records of dates of the shipments to each customer and the quantities supplied in each shipment.
3. Copies of the bill of lading that accompanies each shipment of the TME substance.

TME-91-24

Date of Receipt: August 5, 1991.
Notice of Receipt: August 21, 1991 (56 FR 41560).
Applicant: Confidential.
Chemical: (G) Polyisobutylene amine (PIBA).
Use: (G) Gasoline additive.
Production Volume: Confidential.
Number of Customers: Confidential.
Test Marketing Period: Confidential.
Risk Assessment: EPA identified no significant health or environmental concerns for the test market substance. Therefore, the test market activities will not present any unreasonable risk of injury to health or the environment.

The Agency reserves the right to rescind approval or modify the conditions and restrictions of an exemption should any new information that comes to its attention cast significant doubt on its finding that the test marketing activities will not present any unreasonable risk of injury to health or the enviornment.

Dated: September 16, 1991.

John W. Melone,

Director, Chemical Control Division, Office of Toxic Substances.

[FR Doc. 91-22964 Filed 9-23-91; 8:45 am]

BILLING CODE 6560-50-F

FEDERAL MARITIME COMMISSION

Maryland Port Administration et al.; Agreement(s) Filed

The Federal Maritime Commission hereby gives notice of the filing of the following agreement(s) pursuant to section 5 of the Shipping Act of 1984.

Interested parties may inspect and obtain a copy of each agreement at the Washington, DC Office of the Federal Maritime Commission, 1100 L Street NW., room 10325. Interested parties may submit comments on each agreement to the Secretary, Federal Maritime Commission, Washington, DC 20573, within 10 days after the date of the **Federal Register** in which this notice appears. The requirements for comments are found in § 572.603 of title 46 of the Code of Federal Regulations. Interested persons should consult this section before communicating with the Commission regarding a pending agreement.

Agreement No.: 224-200566.
Title: Maryland Port Administration and Baltimore Forest Products Terminals Leasing Agreement.
Parties:
Maryland Port Administration ("MPA")
Baltimore Forest Products Terminals ("BALTERM")
Synopsis: The Agreement filed, September 11, 1991, provides for BALTERM to lease from MPA at the Dundalk Marine Terminal, 50,000 square feet in Shed 6; 100,000 square feet at Shed 4 and 5.39 acres of space located on the Northwest corner of North Service and Third Streets, which includes a storage shed consisting of 142,500 square feet at the Dundalk Marine Terminal.

Dated: September 18, 1991.

By Order of the Federal Maritime Commission.

Joseph C. Polking.

Secretary.

[FR Doc. 91-22921 Filed 9-23-91; 8:45 am]

BILLING CODE 6730-01-M

GENERAL SERVICES ADMINISTRATION

Office of Business, Industry and Governmental Affairs Business Advisory Board

Meeting Notice: Notice is hereby given that the General Services Administration (GSA) Business Advisory Board will meet October 17, 1991, from 10 a.m. to 3 p.m. at GSA's Central Office, 18th and F Streets NW., room 5141A, Washington, DC. Notice is required by the Federal Advisory Committee Act, 5 U.S.C. app. 2, and the implementing regulation, 41 CFR 101-6.

The purpose of the meeting is to provide a forum for discussion on key business and industry trends, emerging technologies and products, and other issues that may affect GSA's future policy and program formulation. The agenda for this meeting will include discussion on: commercial product acquisition reform; standards (national and international); customer satisfaction measurements; and internal and external communications.

The meeting will be open to the public.

For further information, contact Mary Ann Webster (202/501-4177) of the Office of Business, Industry and Governmental Affairs, GSA/AL, Washington, DC, 20405.

Dated September 16, 1991.

Donald C.J. Gray,

Associate Administrator for Business, Industry and Governmental Affairs, GSA.

[FR Doc. 91-22900 Filed 9-23-91; 8:45 am]

BILLING CODE 6820-34-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Request for Nominations for Members on Public Advisory Committees; OTC Drugs Advisory Committee

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting nominations for six voting members and one nonvoting representative of industry interests to serve on the OTC Drugs Advisory Committee in FDA's Center for Drug Evaluation and Research. Elsewhere in this issue of the **Federal Register**, FDA is publishing a final rule announcing the establishment of this committee.

DATES: Nominations should be received on or before October 24, 1991.

ADDRESSES: All nominations for membership, except for consumer-nominated members and the nonvoting representative of industry interests, should be sent to Jack Gertzog (address below). All nominations for the consumer-nominated members should be sent to Naomi Kulakow (address below). All nominations for the nonvoting representative of industry interests should be sent to William E. Gilbertson (address below).

FOR FURTHER INFORMATION CONTACT: *Regarding all nominations for membership, except for consumer-nominated members:* Jack Gertzog, Center for Drug Evaluation and Research (HFD-9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455.

Regarding all nominations for consumer-nominated members: Naomi Kulakow, Office of Consumer Affairs (HFE-20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5006.

Regarding all nominations for the nonvoting representative of industry interests: William E. Gilbertson, Center for Drug Evaluation and Research (HFD-210), Food and Drug

Administration, 7520 Standish Place, Rockville, MD 20855–2737, 301–295–8000.

SUPPLEMENTARY INFORMATION: FDA is requesting nominations for six members on the OTC Drugs Advisory Committee. The function of the committee is to review and evaluate available data concerning the safety and effectiveness of over-the-counter (nonprescription) human drug products for use in the treatment of a broad spectrum of human symptoms and diseases and advise the Commissioner of Food and Drugs either on the promulgation of monographs establishing conditions under which these drugs are generally recognized as safe and effective and not misbranded or on the approval of new drug applications. The committee will serve as a forum for the exchange of views regarding the prescription and nonprescription status of these various drug products and combinations thereof. The committee may also conduct peer review of agency sponsored intramural and extramural scientific biomedical programs in support of FDA's mission and regulatory responsibilities.

Persons nominated for membership shall be knowledgeable in the fields of internal medicine, family practice, clinical toxicology, clinical pharmacology, pharmacy, and related specialties. The committee may include one technically qualified member who is identified with consumer interests and is recommended by either a consortium of consumer-oriented organizations or other interested persons. A representative of industry interests will serve as a nonvoting liaison. The term of office is 4 years, except that initial appointments will be staggered to permit an orderly rotation of membership.

Interested persons may nominate one or more qualified persons for membership on the advisory committee. Nominations shall state that the nominee is willing to serve as a member of the advisory committee and appears to have no conflict of interest that would preclude committee membership. Potential candidates will be asked by FDA to provide detailed information concerning such matters as financial holdings, consultancies, and research grants or contracts to permit evaluation or possible sources of conflict of interest.

Selection of a representative of consumer interests is conducted through procedures which include use of a consortium of consumer organizations which has the responsibility for screening, interviewing, and recommending candidates for the agency's selection. Candidates should possess appropriate qualifications to understand and contribute to the committee's work.

Regarding nominations for a nonvoting member representing industry interests, a letter will be sent to each person who has made a nomination, and to those organizations indicating an interest in participating in the selection process, together with a complete list of all such organizations and the nominees. The letter will state that it is the responsibility of each nominator or organization indicating an interest in participating in the selection process to consult with the others in selecting a single member representing industry interests within 60 days after receipt of the letter. If no individual is selected within 60 days, the agency will select the nonvoting member representing industry interests.

FDA has special interest in assuring that women, minority groups, and the physically handicapped are adequately represented on advisory committees and therefore extends particular encouragement to nominations for appropriately qualified female, minority, or physically handicapped candidates.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. App. 2), section 903 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 394) as amended by the Food and Drug Administration Revitalization Act (Pub. L. 101–635), and 21 CFR part 14, relating to advisory committees.

Dated: September 16, 1991.

Michael R. Taylor,

Deputy Commissioner for Policy.

[FR Doc. 91–22984 Filed 9–23–91; 8:45 am]

BILLING CODE 4160–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 91F–0342]

Ciba Geigy Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Ciba Geigy Corp. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of 2,2'-methylenebis(4-methyl-6-*tert*-butylphenol)monoacrylate as a stabilizer for adhesives intended for use in food-contact applications.

FOR FURTHER INFORMATION CONTACT: Vir Anand, Center for Food Safety and Applied Nutrition (HFF–335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–472–5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 1B4284) has been filed by Ciba-Geigy Corp., Seven Skyline Dr., Hawthorne, NY 10532–2188.

The petition proposes to amend the food additive regulations to provide for the use of 2,2'-methylenebis(4-methyl-6-*tert*-butylphenol)monoacrylate as a stabilizer for adhesives complying with § 175.105 *Adhesives* (21 CFR 175.105) and § 175.125 *Pressure-sensitive adhesives* (21 CFR 175.125) intended for use in food-contact applications.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: September 16, 1991.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 91–22942 Filed 9–23–91; 8:45 am]

BILLING CODE 4160–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 91P–0335]

Canned Tuna Deviating From Identity Standard; Temporary Permit for Market Testing

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a temporary permit has been issued to Bumble Bee Seafoods, Inc., to market test products designated as "chunk light tuna with jalapeno in water" and "chunk light tuna with jalapeno in oil"

that deviate from the U.S. standard of identity for canned tuna (21 CFR 161.190). The purpose of the temporary permit is to allow the applicant to measure consumer acceptance of the products, identify mass production problems, and assess commercial feasibility.

DATES: This permit is effective for 15 months, beginning on the date the food is introduced or caused to be introduced into interstate commerce, but not later than December 23, 1991.

FOR FURTHER INFORMATION CONTACT: Michelle A. Smith, Center for Food Safety and Applied Nutrition (HFF–414), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–485–0106.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 130.17 concerning temporary permits to facilitate market testing of foods deviating from the requirements of the standards of identify promulgated under section 401 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 341), FDA is giving notice that a temporary permit has been issued to Bumble Bee Seafood, Inc., 5775 Rosco Ct., San Diego, CA 92123.

The permit covers limited interstate marketing tests of canned tuna products formulated by adding chopped or diced jalapeno peppers that have been previously prepared and packed in brine. The food deviates from the U.S. standard of identity for canned tuna (21 CFR 161.190) in that the products contain diced or chopped green jalapeno peppers. The amount of Jalapeno peppers added will not exceed 10 percent of the water capacity of the can. Jalapeno peppers will replace part of the liquid (water or oil) and will not affect the tuna fish fill portion. The test products meet all requirements of the standards with the exception of this deviation. Because test preferences vary by area, along with social and environmental differences, the purpose of the permit is to test the product in various states in the southwestern United States.

For the purpose of this permit, the names of the products are "chunk light tuna with jalapeno in water" and "chunk light tuna with jalapeno in oil." The information panels of the labels will bear nutrition labeling in accordance with 21 CFR 101.9.

This permit provides for the temporary marketing of 300,000 cases containing 24 cans of tuna with jalapeno peppers in spring water, each can weighing 175 grams (g)(6⅛ ounces), and 300,000 cases containing 24 cans of tuna with jalapeno peppers in soybean oil, each can weighing 175 g (6⅛ ounces). The products will be manufactured at Bumble Bee Seafoods, Inc., Santa Fe Springs, CA 90067, and Bumble Bee International, Inc., Mayaguez, Puerto Rico 00708. The products will be distributed in Arizona, California, Colorado, Nevada, New Mexico, and Texas.

Each of the ingredients used in the food must be declared on the labels as required by the applicable sections of 21 CFR part 101. This permit is effective for 15 months, beginning on the date the foods are introduced or caused to be introduced into interstate commerce, but not later than December 23, 1991.

Dated: September 13, 1991.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 91–22943 Filed 9–23–91; 8:45 am]

BILLING CODE 4160–01–M

National Institutes of Health

National Institute of Arthritis and Musculoskeletal and Skin Diseases; Meeting, National Advisory Board for Arthritis and Musculoskeletal and Skin Diseases

Pursuant to Public Law 92–463, notice is hereby given of this meeting of the National Advisory Board for Arthritis and Musculoskeletal and Skin Diseases on October 27, 1991. The meeting will be held at the Bethesda Marriott Hotel, 5151 Pooks Hill Road, Bethesda, Maryland 20814. The board will meet October 27, 7 p.m. to approximately 10 p.m.

The meetings, which will be open to the public, are being held to discuss the Board's activities and to continue evaluation of the National effort to combat arthritis and musculoskeletal and skin diseases. Attendance by the public will be limited to space available.

Ms. Geraldine B. Pollen, Executive Director, National Advisory Board for Arthritis and Musculoskeletal and Skin Diseases, 1801 Rockville Pike, suite 500, Rockville, Maryland 20852, (301) 496–6045, will provide on request an agenda and roster of the members. Summaries of the meeting may also be obtained by contacting her office.

Dated: September 17, 1991.

Samuel C. Rawling,

Acting NIH Committee Management Officer.

[FR Doc. 91–22924 Filed 9–23–91; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Extension of Public Comment Period on the Draft Revised Recovery Plan for the Southern Sea Otter

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Draft revised recovery plan; extension of public comment period.

SUMMARY: The U.S. Fish and Wildlife Service (Service), under the Endangered Species Act of 1973, as amended (Act), gives notice that the public comment period on the draft revised recovery plan for the southern sea otter (*Enhydra lutra nereis*) is extended for 30 days.

DATES: The comment period on the draft revised recovery plan for the southern sea otter is extended until November 1, 1991. Comments on the draft must be received on or before this date.

ADDRESSES: Persons wishing to review the draft revised recovery plan may obtain a copy by written request addressed to the Ventura Field Office, U.S. Fish and Wildlife Service, 2140 Eastman Avenue, suite 100, Ventura, California, 93003, or the Assistant Regional Director, Fish and Wildlife Enhancement, U.S. Fish and Wildlife Service, 911 NE. 11th Avenue, Portland, Oregon 97232–4181. Written comments and materials regarding the plan should be addressed to Mr. Carl Benz at the above Ventura, California address. Comments and materials received are available upon request for public inspection, by appointment, during normal business hours at the above Ventura, California address.

FOR FURTHER INFORMATION CONTACT: Mr. Carl Benz at the above Ventura, California address (telephone 805–644–1766 or FTS 983–6039).

SUPPLEMENTARY INFORMATION:

Background

Restoring endangered or threatened animals and plants to the point where they are again secure self-sustaining members of their ecosystems is a primary goal of the Service's endangered species program. To help guide the recovery effort, the Service is working to prepare recovery plans for most of the listed species native to the United States. Recovery plans describe actions considered necessary for the conservation of the species, establish criteria for the recovery levels for downlisting or delisting them, and estimate time and cost for implementing the recovery measures needed.